Commentary on the EMA Guideline on strategies to identify and mitigate risks for first-in-human and early clinical trials with investigational medicinal products (EMEA/CHMP/SWP/28367/07 Rev. 1.

7 May 2018. doid: 10.1111/bcp.13550

van Gerven J, Bonelli M

View publication

Commentary on the EMA Guideline on strategies to identify and mitigate risks for first‐in‐human and early clinical trials with investigational medicinal products (EMEA/CHMP/SWP/28367/07 Rev. 1

Advancing the boundaries of clinical drug development

Wondering how we can help you? Reach out to us.

contact